9-month revenue of $18.8 million, representing a 75% increase from 2023. Consolidated Gross Margins of 57%, during Q3 2024. TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce results Q3... Read More

TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement offering of 2,666,701 ‎‎units of the Company (the “ Units... Read More

TORONTO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce a large-scale medical cannabis real world evidence study through the MyMedi.ca medical cannabis care platform (“Study”). The Study is to be led... Read More

TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce it has cleared and fully repaid $1,445,000 that was owed under the Debentures of August 2 2023. About... Read More

TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement offering of 6,620,692 ‎‎units of the Company (the “... Read More

USPTO issues Patent No. US 20230025693A1 (“Patent”) that covers Avicanna’s deep penetrating topical cannabinoid composition and methods for treating musculoskeletal inflammation and pain TORONTO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived... Read More

TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority-owned... Read More

Q2 2024 revenue of $6.1 million an increase of 85% over Q2 2023 Completion of two real world evidence trials on Epidermolysis Bullosa and Musculoskeletal Pain TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products reports... Read More

TORONTO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products announces a change of auditors from Kingston Ross Pasnak LLP (“Former Auditor”) to Ramirez Jimenez International CPAs (“Successor Auditor”) effective August 2, 2024... Read More

This marks the first export into Asia, the 18 th international market for Aureus branded products and 21 st market for all Avicanna products TORONTO, July 11, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ( “Avicanna” or the “Company” ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce... Read More

TORONTO, July 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that all of management’s nominees listed in the Company’s Management Information Circular dated May 31, 2024 (“Circular”) were elected as... Read More

TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that as previously disclosed its annual general meeting will be held virtually on Wednesday, July 10, 2024 at 10:30 AM (Toronto Time) (“... Read More

TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce the United States Patent and Trademark Office (“ USPTO ”) issuance of the Patent covering Avicanna’s SEDDS oral cannabinoid compositions and... Read More

TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce Aras Azadian CEO of Avicanna will be delivering a presentation live at the Life Science Investor Forum with Virtual Investor Conference hosted... Read More

Best Quarterly Results in Company’s History from a Financial Perspective. EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies. Marketing Authorization of Trunerox™ in Colombia by INVIMA for Patients with LGS and DS in Colombia. TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company... Read More

The study conducted at The Hospital for Sick Children evaluated wound healing, pain, and itch. 55% of patients enrolled in Study reported improvements in wound healing, 45% displayed wound stability. TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of... Read More

TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private placement offering of 5,313,959 ‎‎units of the Company (the “ Units ”) at a price of $0.40 per... Read More

TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of its observational... Read More

$16.8M in Revenue, representing an increase of 314% from 2022 $6.7M Consolidated gross Profit, representing an increase of 500% from 2022 TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development,... Read More

The 10% CBD (THC free) proprietary oral formulation branded as RHO Phyto Micro Drop 100 in Canada RHO Phyto Micro Drop 100 is available exclusively at MyMedi.ca. TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused... Read More

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, invites interested parties to participate in a conference call with Aras Azadian, Chief Executive Officer, and also Phil Cardella, Chief Financial Officer where Mr.... Read More

TORONTO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that the Company will host a medical symposium entitled “Cannabinoid-based Medicine in the Canadian Healthcare System – From Emerging... Read More

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce it has entered into a research collaboration with a multi-national European-based pharmaceutical company (“ Collaborator ”). The research... Read More

TORONTO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the Company’s first indication-specific... Read More

Exclusive supply agreement for two of Avicanna’s proprietary topical products in the European region Right of first refusal agreement for the Avicanna’s SEDDs capsules in the European region TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc . (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of... Read More

TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce ANVISA has granted commercialization approval of Ease Labs Pharma (“ Ease Labs ”) pharmaceutical preparation produced in Brazil containing... Read More

TORONTO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement offering of 2,537,508 ‎‎units of the Company (the “... Read More

Acquisition of Medical Cannabis by Shoppers assets leading to the launch of MyMedi.ca. Record revenue of $6.27M, representing an increase of 90% over Q2, and 713% year-over-year. Improvements in performance including 46% consolidated gross margins and adjusted EBITDA of ($400k) TORONTO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical... Read More

TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the commercialization of proprietary cannabinoid-based products and a medical cannabis care platform is pleased to announce the appointment of Paul Fornazzari to the board of directors. Paul Fornazzari is a business executive, securities lawyer, and board... Read More

TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, invites interested parties to participate in a conference call with Aras Azadian, Chief Executive Officer, and also Phil Cardella, Chief Financial Officer where Mr.... Read More

TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc . (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased provide an update on the progress of its new cannabis care platform MyMedi.ca since its’ successful launch nationwide in Canada on August 1, 2023. “We are... Read More

TORONTO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products announces today that Chandra Panchal, PhD is retiring as Chairman of the Board of Directors and that it will initiate a search for a new director. “We wish to... Read More

TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased announce the filing of interim financial statements for the three-month period ending June 30, 2023 (“Q2 2023”). Aras Azadian, CEO stated, “We are pleased... Read More

TORONTO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial stage, and international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement (the “ Offering ”) of 1,455,000... Read More

Completed the acquisition of the Medical Cannabis by Shopper’s Drug Mart business. Launch of Avicanna’s new medical cannabis care platform MyMedi.ca. TORONTO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to... Read More

The MyMedi.ca medical cannabis care platform is preparing to launch August 1, 2023 The new cannabis care platform will offer a diverse portfolio of products, including 35 brands and over 200 SKUs selected from various Canadian Licensed Producers TORONTO, July 28, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the... Read More

TORONTO, July 17, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority owned subsididery Santa Marta Golden Hemp the Company has completed the commercial export of aureus branded... Read More

TORONTO, June 28, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce a corporate update and preliminary financial results of Q2-2023. The update includes: Q2-2023 Revenues: Q2-2023 revenues of approximately $3.3M... Read More

Avicanna’s proprietary SEDDS technology capsules are designed for enhanced and rapid absorption of cannabinoids. Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary SEDDS technology capsules across Canadian adult use, medical and international channels. TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a... Read More

TORONTO, June 22, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has entered into a sponsorship agreement with the Canadian Consortium for the Investigation of Cannabinoids (“ CCIC ”) to... Read More

This Research Collaboration will be led by Dr. Jessica Kalra’s research team and focus on characterization of Avicanna’s proprietary products and drug pipeline formulations This Research Collaboration has awarded a two-year grant by the Natural Sciences and Engineering Research Council of Canada TORONTO, June 13, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a... Read More

TORONTO, May 29, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce the execution of the definitive Asset Purchase Agreement (“Agreement”) between Shoppers Drug Mart ® (“Shoppers”) and Avicanna for Avicanna’s... Read More

TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development, ‎advancement, and commercialization of evidence-based, cannabinoid-based products‎, is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated April 14,... Read More

TORONTO, May 16, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased announce the filing of interim financial statements for the three-month period ending March 31, 2023 (“Q1 2023”). Aras Azadian, CEO stated, “We are... Read More

MyMedi.ca to provide Medical Cannabis by Shoppers patients a complete medical cannabis care platform including curated products and services. NGC will facilitate inventory management and fulfillment through its EU GMP-certified and Health Canada licensed infrastructure starting Q2, 2023. TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a... Read More

92% Y-Y increase in Canadian product sales, driven by increased number of commercial SKUs and listings. $4M in revenue, representing 24% Y-Y growth coupled with reduction in SG&A and 35% in EBITA improvements. TORONTO, April 03, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and... Read More

TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that Shoppers Drug Mart ® (“ Shoppers ”) has selected Avicanna as its partner to transition its Medical Cannabis by Shoppers business. Shoppers... Read More

TORONTO, March 21, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement offering of 3,096,230 ‎‎units of the Company (the “ Units... Read More

The initial line of Viola-branded products will include proprietary formulations in vaporizer formats for patients with medical authorizations through the Special Access Program. The prescription products will be commercialized in partnership with IPS Pharma, an established company with more than 20 years of experience with... Read More

TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, announces that the Company has entered agreements with the holders (the “ Holders ”) of convertible debentures (the “ Debentures ”)... Read More

This export marks Avicanna’s 19 th new international market for Avicanna and the 16 th for Aureus branded products. TORONTO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and... Read More

TORONTO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, announces an organizational change in Avicanna LATAM S.A.S. with Lucas Nosiglia stepping down as President of Avicanna LATAM S.A.S.... Read More

TORONTO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial-stage, international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based, cannabinoid-based products, today announced the promotion of Phillip Cardella to Chief Financial Officer (CFO) effective immediately. Mr. Cardella has served as... Read More

TORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc . (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it will be initiating an observational real-world evidence (“RWE”) study using RHO Phyto branded Cannabigerol (“CBG”) transdermal gel... Read More

Developed through Avicanna’s scientific platform, the patent-pending technology provides infusion of a range of cannabinoids into various beverages Initial commercial use of the technology is a THC beverage infuser under the Viola brand available in Ontario through the Ontario Cannabis Store and expanding into other adult use... Read More

TORONTO, November 14, 2022 (GLOBE NEWSWIRE) — Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending September 30, 2022 (“ Q3 2022 ”). Management... Read More

TORONTO, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement offering of 1,790,750 ‎‎units of the Company (the “... Read More

Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid based products, announces that it has entered into a extension agreement (the “ Extension Agreement ”) in connection with its senior secured term loan previously announced on August 19, 2021 (the “ Term Loan ”). In... Read More

Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has formalized its provisional patent application, entitled "Methods for Reducing or Eliminating Incidence of Seizures and Sudden Unexpected Death in Epilepsy", for the... Read More

The education portal provides modules, case studies and other resources related to medical cannabis for Health Care Professionals Established with the support of experts in the fields of pain management, neurology, and dermatology, the portal is designed to address potential gaps in knowledge and training related to the... Read More

Dr. Mac Burnham’s team will explore Avicanna’s drug candidate and its proprietary combination of cannabinoids in pre-clinical model for seizures. Avicanna further expands its current research and commercial focus in Epilepsy which is supported by current medical cannabis sales and on-going research with UHN Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage,... Read More

Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated July 28, 2022 (the “ Circular ”) were elected as directors of the Company at... Read More

Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a strategic non-brokered private placement offering of 7,949,433 ‎‎units of the Company (the “Units”) at a price of $0.35 per Unit for aggregate gross proceeds of... Read More

Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending June 30, 2022 (“ Q2 2022 ”). “We are pleased to report on our continued progress and global... Read More

Psilly™ branded functional fungi-based products will be developed by Avicanna utilizing Avicanna’s proprietary delivery systems and scientific platform Avicanna Inc. (" Avicanna " or the " Company” ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and... Read More

Avicanna Inc. (" Avicanna " or the " Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that its annual general and special meeting of shareholders will be held virtually on August 31, 2022 at 10:30 AM (Toronto Time) (the “ Meeting ”). Materials for the meeting (the “... Read More

The exclusive distribution agreement with Bio-Gate AG includes 5 SKUs from Pura H&W’s evidence-based derma-cosmetics portfolio Initial portfolio launch is planned for Germany, Austria, and Switzerland in Q3 2022 Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company... Read More

Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce the sale of its stake in Sativa Nativa S.A.S. ( “Sativa Nativa” ), which was the Company’s secondary majority owned Colombian subsidiary. The aggregate price paid by the purchaser for... Read More

This export marks the 16 th international market entry for Avicanna and the first export of proprietary genetics into Africa. Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived... Read More

Avicanna Inc . (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp... Read More

Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filing of its interim financial statements for the three-month period ending March 31, 2022 (“ Q1 2022 ”) and the transition of the role of Chief Financial Officer. “We are... Read More

Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, and Ei.Ventures Inc., a technology company empowering mental wellness through psychoactive compounds, nutraceuticals and web 3.0, are pleased to announce several strategic investments to advance the combined company's business plan. Ei.Ventures completed its Regulation A+ financing... Read More

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based... Read More

Avicanna introduces the rare cannabinoid CBG into its RHO Phyto product formulary which includes oral, sublingual, and transdermal formulations RHO Phyto CBG products will be made available through various medical and adult-use channels across Canada by Q3 2022 Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and... Read More

Avicanna Inc. ( " Avicanna" or the "Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development and commercialization of plant-derived medical and pharmaceutical cannabinoid-based products, is pleased to announce that it has entered into an exclusive license and supply agreement with an established South American pharmaceutical company to commercialize up to four (4) of Avicanna’s... Read More

The exclusive distribution agreement includes 5 SKUs from Pura H&W’s evidence-based derma-cosmetics portfolio The products will be commercialized through Bio-Gate’s existing distribution channels with initial launches planned for Germany, Austria, and Switzerland in 2022 Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN)... Read More

$3.3M in revenue representing 108% Y-Y growth, significant growth in finished product sales Total of 4 brands, 16 SKU’s and 35 “cannabis 2.0” listings across medical and retail channels in Canada Expansion of international footprint with entrance into Avicanna’s 14 th international market Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the... Read More

Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the development advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement offering of 7,210,194 ‎‎units of the Company (the “ Units ”) at a price of $0.35 per Unit for... Read More

Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has executed a non-binding... Read More

Expansion and fortification of relationship since 2020 with established pharmaceutical company in Chile Supply of Avicanna’s active pharmaceutical ingredients for existing commercial and pipeline of pharmaceutical products in South America Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a... Read More

Avicanna USA Inc. together with Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce the appointment of Stephen Kim as the Avicanna’s Chief Legal Officer & General Counsel. Mr. Kim comes with over twenty years... Read More

Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the appointment of Eileen McCormack to, and the resignation of Setu Purohit from, its board of directors effective immediately. Eileen McCormack is an experienced senior marketing... Read More

First commercial export of Cannabigerol (CBG), a rare cannabinoid, into Czech Republic This export represents the 14 th international market entrance for Avicanna products Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and... Read More

The THC-Free, CBD derma-cosmetic brand is the first known CBD skincare line to be clinically tested and commercialized across four international markets The initial launch of Pura H&W will include seven SKUs of proprietary products that will be available through e-commerce as well as cannabis and non-cannabis specific... Read More

re+PLAY is a sports performance and recovery-focused brand founded by NBA veteran Al Harrington with and evidence-based CBD formulations developed in partnership with Avicanna Products will be available across adult use channels in Alberta and Ontario and medical channels in partnership with Medical Cannabis by Shoppers™ This... Read More

Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announced today it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the company will be participating in a webcasted... Read More

Proprietary formulations include a range of liquids, capsules, powders, and controlled release tablets utilizing Avicanna’s self-emulsifying drug delivery systems (SEDDS) technology The advanced formulations offer enhanced stability, bioavailability and controlled release of cannabinoids including (CBD, THC, CBG, CBN and THCv) Avicanna intends to utilize the technology in its medical and pharmaceutical products and develop... Read More

Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has entered into a partnership with an established Argentine pharmaceutical company to register and commercialize Avicanna’s proprietary cannabinoid-based pharmaceutical... Read More

Starting with 3 SKUs, the advanced medical cannabis formulary will be available for the medical community and patients through prescription Distribution partnership with Bryden Stokes Limited includes initial focus on Barbados with plans to expand further into the Caribbean region Third active country for RHO Phyto... Read More

Record gross revenue of $1,007,033 through steady growth and progression of global commercialization Delivered a record number (27,041) of units of cannabis 2.0 products globally, an increase of 61% from Q2 25 listings of cannabis 2.0 products across adult use and medical channels in Canada. Expanded into and completed exports into the 12 th international market. Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX:... Read More

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of organic and sustainable plant-derived cannabinoid-based products announces that Flavio Jose Zaclis has resigned as a director of the Company effective immediately for personal reasons. Aras Azadian, Chief Executive Officer, commented “We wanted... Read More

Avicanna’s partnership with Viola brings the equity-focused brand founded by NBA veteran, Al Harrington, to Canada for the first time. Initial products will be available nationwide on the medical cannabis by Shoppers online platform followed by adult use channels including Ontario and New Brunswick Avicanna Inc . ("Avicanna"... Read More

Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has scheduled a conference call on Friday, November 12, 2021 at 8:30AM Eastern Time to discuss the results of its fiscal third quarter ended September 30, 2021 (“Q3 2021... Read More

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products announces that, with immediate effect, Setu Purohit will no longer serve as President and Chief Legal Officer of the Company. He will remain a member of the Company’s board of... Read More

The certification will allow the Company’s Aureus-branded raw material business with sales in 11 countries to include low cost and sustainable cannabis biomass for sale and export to the global marketplace The GACP certification for herbal starting materials of the European Medicines Agency is a pre-requisite for GMP extraction and a requirement for export of cannabis biomass into Europe. Avicanna Inc. (" Avicanna " or the "... Read More

The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products. Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based... Read More

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement (the " Offering "). Under the Offering, the Company has issued an aggregate of 4,587,022 units (the "... Read More

This marks Avicanna’s first commercial exports of proprietary genetics in the form of feminized seeds into the Peruvian and the Argentine medical cannabis markets. Avicanna worked closely with the Colombian and Argentine ministries of agriculture to establish the phyto-sanitary requirements to allow for continuous supply to... Read More

Research findings originated from cannabinoid-based collaboration with leading epilepsy researcher, Dr. Peter Carlen, at UHN that is also supported by a Mitacs Accelerate program grant. Avicanna’s proprietary formulation showed promising pre-clinical results in reducing seizures and will be developed through the company’s pharmaceutical development pipeline as an epilepsy drug candidate. Avicanna Inc. (" Avicanna " or the "... Read More

Four SKUs of Pura Earth branded dermacosmetics have been successfully registered with ARCSA, imported into Ecuador, and will be distributed and commercialized through previously announced partnership with Spenta S.A. This marks the 12 th country and market opening of Avicanna’s product offerings. Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the... Read More

EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 16 th Emerging Growth Conference. The Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for... Read More

Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the failure-to-file cease trade order (the " CTO ") issued by the Ontario Securities Commission on June 11, 2021 has been revoked effective September 10, 2021. The Company will... Read More

Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15... Read More

Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the filing of the Company’s unaudited interim financial statements for the three- and six-month period ended June 30, 2021, accompanying management’s discussion and analysis and related... Read More

Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announces the filing of the Company’s unaudited interim financial statements for the three month period ended March 31, 2021, and accompanying management’s discussion and analysis, and related... Read More

Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announces the filing of the Company’s audited annual financial statements for the year ‎ended December 31, 2020, and accompanying management’s discussion and analysis, annual information form and related... Read More

This initial export to Brazil marks Avicanna’s first commercial export of psychoactive Cannabis Extracts into the emerging Brazilian medicinal cannabis market and the delivery of the initial purchase order from the previously announced three (3) year master supply agreement. This shipment also marks the 11 th country to which SMGH has exported the Aureus™ branded products, which include a range of CBD, THC and CBG extracts... Read More

Initial listings of topical SKUs include 3 Pura Earth branded facial topical products and 1 RHO Phyto branded Extra Strength Deep Tissue Gel Avicanna’s leadership in the emerging category of topicals, with listings now in 5 provinces, is attributed to the proprietary functional formulations and clinical evidence behind the... Read More

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) is pleased to announce closing of the previously announced secured term loan financing (the “ Term Loan ”) in the principal amount of $2,118,000. The Term Loan is subject to an original issue discount of approximately 15%, such that $1,800,000 was advanced by the lender thereof (the “ Lender ”) to the Company. The Term Loan is due October 19, 2022. The terms of the... Read More

Exclusive licensing of certain of Avicanna’s advanced and evidence-based CBD topical products including its deep tissue and skin care formulations. Heritage to lead medical sales and commercialization across non-competing medical channels in Canada under the Opticann brand. Avicanna Inc. (“ Avicanna '' or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development,... Read More

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) announces that the Ontario Securities Commission (" OSC ") has issued an order dated July 30, 2021 (the “ Partial Revocation Order ”) partially revoking the failure-to-file cease trade order issued against the Company on June 11, 2021 (the " FFCTO ") for failing to file certain outstanding continuous disclosure documents (collectively, the “ Documents ”) within the... Read More

Believed to be the first commercial export of psychoactive THC cannabis extract from Colombia to Peru. This marks Avicanna’s initial entrance into the emerging Peruvian cannabis market where the potential market opportunities also include its cosmetic, medical cannabis, and pharmaceutical products. Avicanna Inc. (" Avicanna "... Read More

This initial export to Austria marks Avicanna’s first commercial export of psychoactive THC Cannabis Extracts into the emerging European medicinal cannabis market. The new decree by the Colombian government is designed to progress commercial initiatives related to the cannabis sector and fortify Colombia’s competitive... Read More

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announces the appointment of Kingston Ross Pasnak LLP (the “Successor Auditor”) as its independent registered public accounting firm, effective July 15, 2021, to hold office until the next annual meeting... Read More

Avicanna’s standardized CBD and THC Cannabis Extracts are to be utilized to produce a range of cannabis-derived products for the Brazilian market of 211 million people. Fulfillment of purchase orders based on preliminary forecasts for 2022 is expected to generate approximately CAD$4 million in revenue for Avicanna. Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical... Read More

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) announced today that the Company’s audit is ongoing and it expects to file the following periodic disclosure documents (collectively, the “ Documents ”) within the next sixty to seventy-five days: audited annual financial statements for the year ended December 31, 2020; management’s discussion and analysis relating to the audited annual financial statements for the... Read More

Initial development is part of a licensing and development agreement between the two companies to develop and deliver dermatology and cosmetic products. Combination of Avicanna’s intellectual property and Bio-Gate’s MicroSilver BG™ technology is aimed to target indications including eczema, acne, and atopic dermatitis. Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical... Read More

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management's nominees listed in the Company's management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna's annual general meeting of shareholders held on June 24, 2021 (the " Meeting "). The detailed results of the vote for the election of directors held at the... Read More

The two THC-Free RHO Phyto products will be available through the Medical Cannabis By Shoppers TM online portal and across specific adult use channels. Avicanna’s commercial products in Canada increase to 10 SKU’s where the CBD only oral products are targeted at patients, wellness focused consumers and new users who seek the... Read More

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) announced today that it has been issued a Cease Trade Order (“ CTO ”) by the Ontario Securities Commission (the “ OSC ”) as it no longer expects to file the following periodic disclosure documents (collectively, the “ Documents ”) by June 11, 2021, as previously disclosed: audited annual financial statements for the year ended December 31, 2020; management’s... Read More

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) is providing this bi-weekly update on the status of the management cease trade order granted on April 12, 2021 (the “ MCTO ”) by its principal regulator, the Ontario Securities Commission under National Policy 12-203 – Management Cease ‎Trade Orders (" NP 12-203 "), following the Company’s announcement on March 29, 2021 (the “ Default Announcement ”) that it was... Read More

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) is announcing that it has commenced mailing its management information circular (the “ Information Circular ”) and related proxy materials in relation to Avicanna’s annual general meeting of shareholders (the “ Meeting ”) to be held on Thursday, June 24, 2021 at 9:00 a.m. (Toronto time). A copy of the Information Circular will be available under Avicanna’s profile... Read More

The THC-Free, CBD derma-cosmetic brand is the first known CBD skincare line to be clinically tested and commercialized across cannabis channels nationwide in Canada. The initial launch of Pura Earth will include 3 products that will be available through Medical Cannabis by Shoppers™ online platform and across adult-use... Read More

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) is providing this bi-weekly update on the status of the management cease trade order granted on April 12, 2021 (the “ MCTO ”) by its principal regulator, the Ontario Securities Commission under National Policy 12-203 – Management Cease ‎Trade Orders (" NP 12-203 "), following the Company’s announcement on March 29, 2021 (the “ Default Announcement ”) that it was... Read More

Avicanna Inc. (“ Avicanna ” or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces that Janet Giesselman has resigned from her role as an independent director of the Company to pursue other opportunities. The Company thanks Ms. Giesselman for her service and her contributions... Read More

Avicanna launches its initiative to supply major Canadian hospitals with its advanced RHO Phyto medical cannabis products supported by education, training, and patient support programs. Seven RHO Phyto products will be available for purchase at Sunnybrook Hospital ’s Odette Cancer Centre pharmacy by patients that have been... Read More

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) is providing this bi-weekly update on the status of the management cease trade order granted on April 12, 2021 (the “ MCTO ”) by its principal regulator, the Ontario Securities Commission under National Policy 12-203 – Management Cease ‎Trade Orders (" NP 12-203 "), following the Company’s announcement on March 29, 2021 (the “ Default Announcement ”) that it was... Read More

Expanding from the successful nation-wide launch in medical-only channels through Medical Cannabis by Shoppers Drug Mart™ the company set out to rapidly commercialize its RHO Phyto products through retail channels and has succeeded in doing so within a three-month period. In collaboration with Velvet’s sale infrastructure, the... Read More

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, April 12, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) announces that, further to its March 29, 2021 news release, its application for a management cease trade order (the “... Read More

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) announces that it will miss the deadline (the “ Filing Deadline ”) of March 31, 2021 to file the following (collectively, the “ Documents ”): the Company’s audited annual financial statements for the years ended December 31, 2020 and 2019, ‎as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure ‎‎Obligations (“ NI 51-102 ”);‎ and the... Read More

Avicanna has been granted its 2021 quota from the Colombian government to cultivate and process up to 10,267 kg of dry flower for exports in the form of crude and standardized extracts and final phyto-therapeutic pharmaceutical products and to produce seeds from registered psychoactive varieties for commercial purposes. This is the first known import of THC Cannabis Extracts into Chile and will be utilized for pharmaceutical... Read More

Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that Avicanna’s Chief Executive Officer, Aras Azadian has been invited to present at the Benzinga Biotech Small Cap Conference (the “ Benzinga Conference ”) and the Virtual Life... Read More

Purpose-driven cannabis brand rooted in social equity and justice to enter Canada Avicanna to lead commercialization through medical and consumer retail sales channels Viola intends to promote various social projects to advance education related to cannabis as well as Viola’s pioneering initiatives to promote diversity, equity, and inclusion in the cannabis industry in Canada Avicanna Inc. (“ Avicanna ” or the “ Company “)... Read More

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, today announced that Aras Azadian, Chief Executive Officer, will present live at LifeSciencesInvestorForum.com on March 25 th . DATE: Thursday, March 25 th TIME: 2pm ET LINK: https://bit.ly/3qVRFyI This will be a live, interactive online... Read More

Avicanna Inc. (" Avicanna " or the " Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that Avicanna’s Chief Executive Officer, Aras Azadian has been invited to present at Inaugural Emerging Growth Virtual Conference , presented by M Vest LLC and Maxim Group LLC. The... Read More

Avicanna Inc. (" Avicanna " or the " Company ") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has closed a non-brokered private placement (the " Offering "). Under the Offering, the Company has issued an aggregate of 4,480,000 units (the "... Read More

Development and licensing of a bespoke and evidence-based athletic line of CBD topical products for the re+PLAY brand in the U.S. Avicanna to lead commercialization in Canada through consumer retail and medical sales channels. Avicanna Inc. (“ Avicanna '' or the “ Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived... Read More

RHO Phyto Deep Tissue Gels will be initially available on the Medical Cannabis by Shoppers Drug Mart™ online platform and expanded into specific consumer retail channels in February 2021. Initiation of osteoarthritis preclinical trials in Canada in addition to the enrollment of the products into the UHN MC-RWE study to evaluate the effectiveness on pain, sleep, anxiety, and depression. Avicanna Inc. (“ Avicanna ” or the “... Read More